This segment encompasses the research, development, manufacturing, and commercialization of innovative vaccines. Dynavax's primary focus is on HEPLISAV-B, a hepatitis B vaccine, which is marketed in the United States and Europe. Research and development activities include clinical trials, formulation improvements, and exploring new applications for CpG 1018 adjuvant technology. The company utilizes advanced biotechnology and immunological approaches to develop effective and safe vaccines. Patient impact is significant, as HEPLISAV-B provides protection against hepatitis B virus infection. Dynavax's market positioning is strengthened by its focus on a high-need area and its partnerships with other pharmaceutical companies. Future opportunities include expanding the use of HEPLISAV-B and developing new vaccine candidates. Regulatory aspects involve obtaining and maintaining approvals from health authorities. Collaborations with Valneva Scotland Limited, Serum Institute of India Pvt. Ltd., and Merck, Sharp & Dohme Corp. support vaccine development and distribution.